Ruxolitinib cream for vitiligo showed 60% of patients maintained benefits post-treatment, with potential for skin repigmentation upon reinitiation. JNJ-2113 demonstrated significant efficacy in plaque psoriasis, achieving primary end point in a phase 2b trial. The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to…